Materials and methods
knee infection, hypersensitivity, knee osteoarthritis
THROMBOEMBOLIC EVENT, SECONDARY OSTEOARTHRITIS, KNEE OSTEOARTHRITIS, BLEEDING DISORDER, HYPERSENSITIVITY
The protocol of this randomized double-blind controlled trial was registered in the Thai Clinical Trials Registry (registration no. TCTR20201126002). Written informed consent was obtained from all study participants. Patients diagnosed with bilateral knee osteoarthritis who were scheduled for primary one-stage SBTKA between 2020 and 2021 were included in this study. Patients having one or more of the following were excluded: history of any previous knee surgery, knee infection, bleeding disorder or thromboembolic event, a diagnosis of secondary osteoarthritis, and/or hypersensitivity to any medication in the study protocol (bupivacaine, tranexamic acid, parecoxib, and morphine sulfate).